Companies › BioVersys SAS
1 active drug program in 5 registered trials: 2 Phase 3, 1 Phase 1, 1 Phase 4, 1 Phase 2; Infectious disease, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Rifabutin (BV100) Bacterial DNA-directed RNA polymerase inhibitor | – | Phase 3 | Hospital Acquired Bacterial Pneumonia (HABP); Healthy Adult Participants; Mycobacterium Abscessus Lung Disease; Prosthetic Infection … | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07514364 | Rifabutin (BV100) | Phase 4 | Mycobacterium Abscessus Lung Disease | Infectious disease | Mar 2026 |
| NCT04672525 | Rifabutin (BV100) | Phase 3 | Prosthetic Infection | Infectious disease | Nov 2026 |
| NCT07580586 | Rifabutin (BV100) | Phase 1 | Healthy Adult Participants | Other | Dec 2026 |
| NCT05766267 | Rifabutin (BV100) | Phase 2 | Tuberculosis, Pulmonary | Infectious disease | Dec 2026 |
| NCT07326540 | Rifabutin (BV100) | Phase 3 | Hospital Acquired Bacterial Pneumonia (HABP) | Infectious disease | Dec 2027 |
No annotated target.
–
Meitheal Pharmaceuticals Avenue Therapeutics Freya Biosciences ApS BioAegis Therapeutics Aligos Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.